The miRNA biogenesis factors, p72/DDX17 and KHSRP regulate the protein level of Ago2 in human cells

Connerty, Patrick; Bajan, Sarah; Reményi, Judit; Fuller-Pace, Frances V.; Hutvágner, György

doi:10.1016/j.bbagrm.2016.07.013

Cited by 16 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past few decades, miRNAs have become essential post-transcriptional regulators of gene expression ( 13 , 14 ). Studies have shown that the abnormal expression of miRNA may be related to the inflammatory response in patients with neonatal sepsis.…”

Section: Discussionmentioning

confidence: 99%

miR-141 is negatively correlated with TLR4 in neonatal sepsis and regulates LPS-induced inflammatory responses in monocytes

Lin

Wang

2021

Braz J Med Biol Res

View full text Add to dashboard Cite

Neonatal sepsis is an inflammatory system syndrome and a main cause of neonatal mortality. However, there is a lack of ideal biomarkers for early neonatal sepsis diagnosis. The aim of this study was to evaluate the clinical significance of miR-141 in sepsis in neonates, and explore the regulatory effects of miR-141 on inflammation in monocytes. This study used qRT-PCR to calculate the expression of miR-141 in the serum of septic neonates. The diagnostic values of procalcitonin (PCT) and serum miR-141 were evaluated by receiver operating characteristic (ROC) curves. The relationship between miR-141 and TLR4 was determined using luciferase reporter assay. An inflammation model was established using monocytes with lipopolysaccharide (LPS) treatment. ELISA assay was used to analyze the levels of pro-inflammatory cytokines. The expression of miR-141 in neonatal sepsis was significantly lower than healthy controls. ROC curves showed that miR-141 had diagnostic accuracy. LPS stimulation in monocytes led to a decrease in the expression of miR-141. A luciferase reporter assay proved that miR-141 targeted TLR4, and a negative correlation of miR-141 with TLR4 was found in septic neonates. ELISA results demonstrated that the overexpression of miR-141 inhibited LPS-induced inflammation in monocytes. In conclusion, serum decreased miR-141 expression served as a candidate diagnostic biomarker of neonatal sepsis. TLR4 is a target gene of miR-141, which may mediate the inhibitory effects of miR-141 overexpression on LPS-induced inflammation in monocytes. Therefore, miR-141 is expected to be a potential diagnostic biomarker and a therapeutic target in neonatal sepsis.

show abstract

Section: Discussionmentioning

confidence: 99%

miR-141 is negatively correlated with TLR4 in neonatal sepsis and regulates LPS-induced inflammatory responses in monocytes

Lin

Wang

2021

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…In the past few decades, miRNA has become an essential post-transcriptional regulator in the regulation of gene expression [14][15][16].Studies have shown that the abnormal expression of miRNA may be related to the in ammatory response in patients with sepsis.For example, miR-26a is down-regulated in blood monocytes and serum in neonatal sepsis [17].As a speci c biomarker, miR-1290 provides a basis for pediatricians to diagnose NEC cases and neonatal sepsis [18]. SNHG16 is able to reverse the effect of miR-15a/16 on the LPS-induced in ammation pathway [19].But there is still a lack of an ideal biomarker for neonatal sepsis early diagnosis.Therefore, exploring new functional miRNAs is of great value for the treatment of neonatal sepsis.…”

Section: Discussionmentioning

confidence: 99%

MIR-141 is Negatively Correlated With TLR4 in Neonatal Sepsis and Regulates LPS-induced Inflammatory Responses in Monocytes

Lin

Wang

2020

Preprint

View full text Add to dashboard Cite

Background: Neonatal sepsis is an inflammatory system syndrome caused by bacteria or viruses, which is the main cause of neonatal morbidity and mortality. But currently there is a lack of an ideal biomarker to meet the standard. The abnormally expression of miRNAs may be a group of potential diagnostic biomarkers in neonatal sepsis.Methods: First, qRT-PCR was used to calculate the expression of miR-141 in the serum of neonatal with sepsis and control. The diagnostic value of PCT and serum miR-141 was evaluated by receiver operating characteristic (ROC) curve. Second, the relationship between miR-141 and TLR4 was verified using luciferase report assay. An inflammation model was established using monocytes with the LPS treatment. Elisa analyzed the relationship between miR-141 and inflammatory factors.Results: qRT-PCR found that the expression of miR-141 in neonatal sepsis was significantly lower than healthy controls. ROC curve shows that miR-141 has high diagnostic accuracy. LPS stimulation in monocytes also led to a decrease in the expression of miR-141. Luciferase report assay proves that miR-141 can target and regulate TLR4 expression. ELISA proved that overexpression of miR-141 has the effect of inhibiting the LPS-induced inflammation in monocytes.Conclusion: In conclusion, miR-141 serves as a candidate diagnostic biomarker and is involved in the regulation of inflammatory response in the development of neonatal sepsis. Overexpression of miR-141 inhibits LPS-induced inflammation by targeting TLR4. Therefore, miR-141 is expected to be a potential diagnostic biomarker and a therapeutic target in neonatal sepsis.

show abstract

“…Up to now, more than 1,500 RBP genes have been founded through genome-wide screening in human genome [10]. RBPs could regulate gene transcription, but mainly act on RNA processing, such as mRNA splicing, localization, polyadenylation, translocation, stability, translation [11,12], which is more rapid than transcription factors mediated regulation [13,14]. Due to the critical roles of post-transcriptional regulation in the development of biology, it is thus reasonable that functional disruption of RBPs are involved into the progression of multiple human diseases, such as U1-70K in Alzheimer's disease [15], muscleblind in neurodegeneration [16,17], FMRP in Fragile X syndrome [18] , quaking (QKI), human antigen R (HuR), and serine/arginine-rich splicing factor 1 (SRSF1) in cardiovascular disease [19].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer

et al. 2020

View full text Add to dashboard Cite

The dysregulation of RNA binding proteins (RBPs) play critical roles in the progression of several cancers. However, the overall functions of RBPs in prostate cancer (PCa) remain poorly understood. Therefore, we first identified 144 differentially expressed RBPs in tumors compared to normal tissues based on the TCGA dataset. Next, six RBP genes (MSI1, MBNL2, LENG9, REXO2, RNASE1, PABPC1L) were screened out as prognosis hub genes by univariate, LASSO and multivariate Cox regression and used to establish the prognostic signature. Further analysis indicated that high risk group was significantly associated with poor RFS, which was validated in the MSKCC cohort. Besides, patients in high risk group was closely associated with dysregulation of DNA damage repair pathway, copy number alteration, tumor burden mutation and low-respond to cisplatin (P < 0.001), bicalutamide (P < 0.001). Finally, three drugs (ribavirin, carmustine, carbenoxolone) were predicted using Connectivity Map. In summary, we identified a six-RBP gene .

show abstract

The miRNA biogenesis factors, p72/DDX17 and KHSRP regulate the protein level of Ago2 in human cells

Cited by 16 publications

References 28 publications

miR-141 is negatively correlated with TLR4 in neonatal sepsis and regulates LPS-induced inflammatory responses in monocytes

miR-141 is negatively correlated with TLR4 in neonatal sepsis and regulates LPS-induced inflammatory responses in monocytes

MIR-141 is Negatively Correlated With TLR4 in Neonatal Sepsis and Regulates LPS-induced Inflammatory Responses in Monocytes

Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer

Contact Info

Product

Resources

About